Connect Biopharma Files 6-K for September 2024
Ticker: CNTB · Form: 6-K · Filed: Sep 6, 2024 · CIK: 1835268
Sentiment: neutral
Topics: reporting, sec-filing, foreign-private-issuer
TL;DR
Connect Biopharma filed its monthly 6-K, confirming 20-F annual reports and US HQ address.
AI Summary
Connect Biopharma Holdings Limited filed a Form 6-K on September 6, 2024, to report its activities for the month of September 2024. The filing indicates that the company is a foreign private issuer and will file its annual reports under Form 20-F. The principal executive office is located at 12265 El Camino Real, Suite 350, San Diego, CA 92130, USA.
Why It Matters
This filing serves as an update for investors regarding Connect Biopharma's ongoing reporting obligations as a foreign private issuer. It confirms their adherence to SEC regulations for the period.
Risk Assessment
Risk Level: low — This is a routine administrative filing and does not contain new financial or operational information that would typically indicate increased risk.
Key Players & Entities
- Connect Biopharma Holdings Limited (company) — Filer of the 6-K report
- 12265 El Camino Real, Suite 350, San Diego, CA 92130, USA (location) — Principal executive office address
FAQ
What type of filing is Connect Biopharma Holdings Limited submitting?
Connect Biopharma Holdings Limited is submitting a Form 6-K, which is a Report of Foreign Private Issuer.
What is the reporting period for this Form 6-K?
The Form 6-K is for the month of September 2024.
Under which form will Connect Biopharma file its annual reports?
Connect Biopharma will file its annual reports under cover of Form 20-F.
What is the principal executive office address for Connect Biopharma?
The principal executive office is located at 12265 El Camino Real, Suite 350, San Diego, CA 92130, USA.
What is the Commission File Number for Connect Biopharma?
The Commission File Number for Connect Biopharma is 001-40212.
Filing Stats: 410 words · 2 min read · ~1 pages · Grade level 10.5 · Accepted 2024-09-06 17:01:14
Filing Documents
- connectform6-kseptember202.htm (6-K) — 18KB
- 0001835268-24-000027.txt ( ) — 19KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Dated September 6, 2024 CONNECT BIOPHARMA HOLDINGS LIMITED By s David Szekeres Name David Szekeres Title President